In a world first, medical regulators in the UK have approved a gene therapy that aims to cure sickle cell disease and beta thalassemia.
The treatment is the first to be licensed using the gene-editing tool known as Crispr, for which its discoverers were awarded the Nobel prize in 2020.
It is a revolutionary advance for two inherited blood conditions, both triggered by errors in the gene for haemoglobin.
In trials, 28 out of 29 sickle cell patients were free of severe pain and 39 of 42 beta thalassemia patients no longer needed blood transfusions for at least a year.
The trials are continuing in the UK, US, France, Germany and Italy.
Please subscribe here: http://bit.ly/1rbfUog
#GeneTherapy #SickleCellDisease #BetaThalassemia #BBCNews
Two people in a serious condition who were evacuated from a Hantavirus-hit cruise ship have arrived in the Netherlands for…
ROMA (ITALPRESS) – La concessione della grazia a Nicole Minetti tiene banco sui nostri media: da quando, lo scorso 11…
CROTONE (ITALPRESS) – Vasta operazione della Polizia giudiziaria, denominata “Welcome”, finalizzata al contrasto dell’immigrazione clandestina. I poliziotti stanno eseguendo 93…
ROMA (ITALPRESS) – Si attende una risposta, che potrebbe arrivare anche in giornata, da parte dell’Iran alla bozza proposta dagli…